论文部分内容阅读
目的探讨慢性阻塞性肺疾病(COPD)稳定期患者的有效治疗方法,以减少COPD急性发作。方法将32例COPD稳定期患者随机分成两组,试验组给予茶碱缓释片0.2mg,口服,每日2次,N-乙酰半胱氨酸(NAC)200mg,口服,每日3次。对照组给予茶碱缓释片0.2mg,口服,每日2次。疗程6个月。在实验前后分别测定肺功能,并比较开始前后6个月两组COPD患者急性发作次数。结果在试验组第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)和FEV1/预计值较试验前均有显著提高(P均<0.01),开始试验6个月较试验前6个月COPD急性发作次数减少(P<0.01)。对照组FEV1、FEV1/FVC和FEV1/预计值与试验前差异无统计学意义(P>0.05),开始试验6个月较试验前6个月COPD急性发作次数比较差异无统计学意义(P>0.05)。结论茶碱缓释片联合NAC治疗能够改善稳定期COPD患者的肺功能及急性发作次数。
Objective To investigate the effective treatment of patients with chronic obstructive pulmonary disease (COPD) in stable phase to reduce the acute episode of COPD. Methods Thirty-two patients with stable COPD were randomly divided into two groups. The experimental group was given 0.2 mg of theophylline sustained-release tablets orally twice daily and 200 mg of N-acetylcysteine (NAC) orally three times a day. The control group was givenophylline sustained-release tablets 0.2mg, orally, 2 times a day. Course of 6 months. Pulmonary function was measured before and after the experiment, and the number of acute exacerbations of COPD patients in both groups was compared before and after 6 months. Results The forced expiratory volume (FEV1), FEV1 / FVC and FEV1 / predicted value in the experimental group were significantly higher than those before the test (all P <0.01) The number of acute exacerbations of COPD decreased in one month (P <0.01). The FEV1, FEV1 / FVC and FEV1 / predicted values in the control group were not significantly different from those before the test (P> 0.05). There was no significant difference in the number of acute exacerbations of COPD in the 6 months before the trial and 6 months before the trial (P> 0.05). Conclusion The theophylline sustained-release tablets combined with NAC can improve pulmonary function and the number of acute attacks in patients with stable COPD.